Citius Pharmaceuticals, Inc. · NASDAQ:CTXR
Citius Pharmaceuticals — Investor Presentation (July 2017)
27 slides from Citius Pharmaceuticals's investor presentation, Jul 13, 2017
Slide 1: Citius Pharmaceuticals, Inc. Investor Presentation
Citius Pharmaceuticals, Inc. Investor Presentation Spring-Summer 2017 XITIUS PHARMA
Slide 2: Disclaimer
Disclaimer ‘This presentation has been prepared by Ciths Pharmaccutia Inc. the “Company” for informational purposes only and not fr any: other purpose. Noth ‘tained tn the preuntation tor should be anstrae na 4 fecommendation, promise or representation by tho preseator ar the Company’ or any directo
Slide 3: Citius Management Team
Citius Management Team Leonard Mazur, Director and Chairman of the Board ‘Mr. Mazur is highly accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding, building and creating value and returns for the investors. He has been instrumental in launching man
Slide 4: Investment Opportunity
Investment Opportunity Olympic Motto: “ ius, Altius, Fortius” (Faster, Higher, Stronger) ¥ Pipeline portfolio of important, high potential, later stage drugs that address unmet medical needs ¥ Adjunctive cancer care, critical care medicine, and Gi disease Y Very low development risk proven drugs tha
Slide 5: Pipeline in Progressive Stages
Pipeline in Progressive Stages Y Phase 3 + Lead product (Mino-Lok) is a unique antibiotic lock therapy that salvages central lines in bacteremic patients, has been granted QIDP, and is entering Phase 3. There is no approved competition nor any on the horizon. v Phase 2 + Gastrointestinal product (to
Slide 6: Development Strategy
Development Strategy Objectives ¥ Identify later stage drug candidates that can be developed within a 3-4 year time horizon ¥ Acquire the most relevant and advanced technologies to provide superior product characteristics and intellectual property protection for 10 years ¥ Focus on therapeutic areas
Slide 7: Antibiotic Lock Therapy for Catheter Related Bloodstream Infections (CRBSI)
Antibiotic Lock Therapy for Catheter Related Bloodstream Infections (CRBS!)
Slide 8: Central Venous Catheters (CVCs), PICCs, and Hemodialysis Catheters
Central Venous Catheters (CVCs) , Peripherally Inserted Central Catheter (PICs), and Hemodialysis Catheters Hemodialysis,
Slide 9: Contaminated Catheter Hub
Contaminated Catheter Hub Endogenous Skin insertion Endogenous Sintra Extrinsic wawhands Contaminated sintectant Hematogenous from distant Infection (10%), Safdar N, Maki DG. The pathogenesis of catheter-elated bloodstream infection with noncuffed short-term ‘central venous catheters. Int Gare Med 2
Slide 10: The CRBSI Challenge: Organisms Protected from Antibiotics
a The CRBSI Challenge: Organisms Protected from Antibiotics arto penetaton + Pathogens attach to the surface of the lumen in a central venous catheter and form colonies. + Colonies grow and exude a fibrous glycocalyx that protects the organisms from antibiotics, even when shown to be sensitive in vi
Slide 11: The Market is Large and Highly Receptive to New Solution
The Market is Large and Highly Receptive to New Solution Annual Incidence of CRBSI Treatments (flushes/locks) Factors [Prert Term CVC | Long Term CVC Number of Catheters 3million ‘4 million ‘Average Duration (days) 2 100 Catheter Days 36 million 400 million Infection Rate 2/1900 days 11000 days Cath
Slide 12: IDSA Guidelines: Treatment of long-term CRBSI
IDSA Guidelines: Treatment of long-term CRBSI | vor cra ecu a 6%) (tt tren MermelLA etal Clin infect Oe 2006149:1-45.
Slide 13: CVC Replacement is Costly and Risky
Slide 14: Locking a Central Venous Line with Mino-Lok
Locking a Central Venous Line with Mino-Lok Mino-Lok™ Instructions for Use Aspirate the contents of the catheter jumen using the known catheter volume a8 a guide for the exact amount of fluid, to withdraw; lumen volume is usually 0.8 to 1.0 ml. Flush each lumen of the catheter with normal saline. In
Slide 15: Phase 2b Trial Results
Phase 2b Trial Results a ae aa Patients (00%) MDAnderson Gancer Center Cancer Type Hematologic 26 @ 8 () Solid wmor 10 3) 2 0) IeUAdmission 4 oO) 4 a Mech, Ventilator 3 ©) ° () Bacteremia Gram 7 or (3) Gam if ay 28 @ ‘Neutropenia (<500 ) 9 ©) 36 (60) (Wleroblologic Eradication 36 (5) Gy (G00) Relaps
Slide 16: Mino-Lok Phase 3 Study Design
Mino-Lok Phase 3 Study Design Multi-center, randomized, double-blind, placebo and active control superiority study Mino Lok Solution + CVC Salvage + SOC IV Antibiotics (n=350) : ; All organisms Patients with CLABSI/CRBSI Control Arm (1 (n=700) Saline-heparin (placebo) + SOC IV Antibiotics for commen
Slide 17: Intellectual Property
Intellectual Property ‘Mino-Lok™ is supported by a robust intellectual property portfolio that provides protection until June 7, 2024 (we have received a QIDP designation providing 5 years market exclusivity, and 3 years of Hatch- Waxman market exclusivity from the time of NDA approval...extends exc
Slide 18: Mino-Lok Development Plan (as of 2/2017)
Mino-Lok™ Development Plan (as of 2/2017) 2013 2014 2015, 2016 2017, 2018 2019 (gifa2 Los Taa|aio2 jas} aa | ot [oz] os]aa) Gi Tar] a3 ]as lar loz ]o3[a4| ai [a2] as[aa|ailaz|asT aa * Zk=@ Fa xx
Slide 19: Mino-Lok (minocycline/disodium edetate/ethyl alcohol)
Mino-Lok™ (minocycline/disodium edetate/ethyl alcohol) ¥ Treats catheter-related blood stream infections (CRBSIs). ¥ Penetrates biofilm, eradicates bacteria and salvages infected, indwelling vascular catheters while providing anti clotting properties, Will be indicated as adjunctive therapy for the
Slide 20: Prescription strength topical for symptomatic hemorrhoid treatment
Prescription strength topical for symptomatic hemorrhoid treatment
Slide 21: Hydro-Lido (hydrocortisone + lidocaine)
Hydro-Lido (hydrocortisone + lidocaine) Citius’ product is expected to be the first FDA-approved prescription product to treat hemorrhoids in the US ' Atany time, up to 5% of the U.S. population suffers from Existing Rx Treatments: “Grandfathered Products hemorrhoids, but there are no FDA-approved p
Slide 22: Phase 2a Trial — Positive Directional Improvement
Phase 2a Trial — Positive Directional Improvement Ina randomized, double blind study of topical Improvement in Global Severity formulations of vehicle and various strengths ‘of components (cream, hydrocortisone, and 69.60 lidocaine), Hydro-Lido (3% hydrocortisone + 5% lidocaine) showed directional i
Slide 23: Phase 2a Trial — Positive Directional Improvement
Ny Phase 2a Trial — Positive Directional Improvement Faster Relief at Day 2* Pruritus Pain and Discomfort Hydro-Lido achieved 88.9% Hydro-Lido achieved 85.7% relief of pain relief at Day 2 compared to any and discomfort at Day 2 compared to any of its components of its components Day 2 Relief (Pruri
Slide 24: Financial Summary
Financial Summary Cap Table as of July 10, 2017 Basic Shares Outstan 5,057,247 Warrants 1,385,245 $3.49 Options 586,034 $8.21 Unit Purchase Options? 201,334 $9.00 Convertible Debt? 957,596 Principal Shareholders (pre-offering) Leonard Mazur (31%) Current Price $6.23 Myron Holubiak (11%) 52 Week High
Slide 25: Competitive Landscape
Competitive Landscape There are no products being developed for treatment of infected central venous lines Cores (Ns USA) Newtroin® ‘Phase 3 teal in Prevention ia HO taurolidine, crate, heparin Great Lakes (US) Butock'™ Approached FDA - Announced a prevention teimethoprim, EDTA, ethanol tral in HD i
Slide 26: Summary
Summary Addressing attractive diversified multi-billion dollar opportunities — Adjunctive Cancer Care, Critical Care Medicine/Infectious Disease, Gastrointestinal Disease Portfolio addressing recognized unmet medical needs with cost-saving or cost-effective solutions with low risk development pathwa
Slide 27: Corporate Profile
Corporate Profile XITIUS PHARMA Media and Investor Rel Citius Pharmaceuticals, Inc. re4) TRTH sero 41 Commerce Drive ns: IRTH Communications First Floor Robert Haag, Managing Director Cranford, NJ 07016 866-976-4784 908-967-6767 CTXR@irthcommunications.com www.citiuspharma.com
Citius Pharmaceuticals — Investor Presentation (July 2017) on 6ix